Purpose: :
Purpose: Intravitreal anti-VEGF therapy has been demonstratedto be an effective treatment modality for nvAMD. Many clinicalstudies that established the beneficial effect of intravitrealanti-VEGF therapy did not include the cohort of patients withpoor presenting visual acuity. Currently, there is little informationregarding the outcomes of anti-VEGF therapy for nvAMD in patientspresenting with poor vision. The purpose of the current studyis to report on the outcomes of intravitreal anti-VEGF therapyfor nvAMD in patients with presenting best corrected visualacuity (BCVA) ≤ 20/400.